'We're disappointed in the outcome': NASA shares photo of sideways Intuitive Machines moon lander, which died 12 hours after touchdown
When you buy through links on our articles, Future and its syndication partners may earn a commission.
The second moon landing attempt by Houston-based Intuitive Machines has ended just as the company's first did — with the lander dead after tipping over on its side inside a lunar crater, a new image confirms.
According to NASA, which hired Intuitive Machines to carry several scientific instruments to the moon as part of its Commercial Lunar Payload Services (CLPS) initiative, the lander prematurely suspended operations on Friday (March 7) when its battery depleted just 12 hours after the fumbled landing.
Before shutting down, the lander's various instruments managed to transmit about 250 megabytes of data to NASA, including a telltale photo showing two of the spacecraft's legs jutting upward, a half-lit Earth hovering majestically in the distance.
Related: Blue Ghost spacecraft captures rare, stunning views of Earth eclipsing the moon
It is not yet clear what went wrong for the IM-2 mission and the Athena lander, which officially touched down on the moon's near-side at 12:30 p.m. EST on Thursday (March 6) and ended operations at 1:15 a.m. on Friday. NASA noted that the spacecraft also landed more than 1,300 feet (400 meters) from its intended landing site near the moon's south pole.
"While we're disappointed in the outcome of the IM-2 mission, we remain committed to supporting our commercial vendors as they navigate the very difficult task of landing and operating on the Moon," Joel Kearns, deputy associate administrator for Exploration in the Science Mission Directorate at NASA Headquarters in Washington, D.C., said in a statement.
This was the second lunar landing attempt for Intuitive Machines in as many years. The company completed its first landing on Feb. 22, 2024, when the Odysseus spacecraft touched down, becoming the first U.S. spacecraft to reach the lunar surface since Apollo 17 in 1972.
RELATED STORIES
—'Everything has changed since Apollo': Why landing on the moon is still incredibly difficult in 2024
—Space photo of the week: 55 years ago, the 'world's loneliest man' snapped this iconic Apollo 11 image
—Pale Blue Dot: The iconic Valentine's Day photo of Earth turns 35 today — and you're probably in it
However, during its descent Odysseus' landing lasers malfunctioned, causing the spacecraft to temporarily lose the guidance needed to estimate landing distances. One of Odysseus' legs snapped on the lunar surface, and the spacecraft fell on its side, limiting some of its functions. The spacecraft fell silent one week after landing, shutting down power before the frigid lunar night set in.
NASA has committed to working with Intuitive Machines on two more lunar deliveries, with its IM-3 mission scheduled for 2026, and IM-4 slotted for 2027.
The landing attempt comes just days after a successful touchdown by rival space company, Firefly Aerospace. The company's Blue Ghost spacecraft aced its landing on Sunday (March 2), sending home an image of the lander's perfectly-upright shadow cast onto the lunar surface. Blue Ghost, also part of the CLPS initiative, has 10 NASA instruments in its lander that will operate on the moon's surface for about 14 Earth days (one lunar day).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Trump's term a ‘rough time for science in America': Ex-NASA astronaut
(NewsNation) — The United States has grown 'completely reliant' on SpaceX, said Col. Terry Virts, a former NASA astronaut and International Space Station commander. 'It's not only NASA, also the Defense Department and the intelligence community are very dependent on SpaceX,' Virts told NewsNation. President Donald Trump has threatened to cut SpaceX contracts amid a public feud with onetime adviser Elon Musk, who briefly countered with a threat to decommission his Dragon space capsule. Pulled NASA nomination blindsides space community: 'Major blunder' Musk's threat has since been walked back, but Virts said it indicates a greater problem: national needs left to Musk's whims. 'I think it's very concerning, especially when the CEO is so unstable and has been so, you know, unpredictable and some might say, dangerous in recent years,' Virts said. Trump's proposed NASA budget would cut $6 billion — the largest single-year cut in the agency's history, according to the nonprofit Planetary Society. Under the budget, human space programs would get a boost, with more than $7 billion allocated for lunar missions and $1 billion allocated for new investments in efforts to get people to Mars. The budget includes significant cuts to staffing, maintenance, environmental compliance, and the space and Earth science programs. 'It has been a chaotic and stressful time. Unfortunately, it affects the nation's space exploration and science community, not only at NASA, but also in the medical research and other fields,' Virts said. Milky Way has 50-50 chance of colliding with neighbor galaxy Musk's company is set to launch Falcon 9 for Axiom Space's Axiom Mission 4 on Tuesday, seemingly signaling a secure partnership between SpaceX and NASA. But Virts warned of overarching damage to the American science community that has been building since Inauguration Day. 'You can't just turn on a space program, and in a matter of months. You can certainly turn it off, and that's what's happened with this administration's chaos,' Virts said. 'But getting it back is going to be a problem.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
20 minutes ago
- Yahoo
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile with no safety signals. 'We are excited by these impressive results from MET-233i, which demonstrate exceptional efficacy with no safety signals, and enable the potential first monthly multi-NuSH combination,' said Steve Marso, M.D., Chief Medical Officer of Metsera. 'We observed five-week body weight loss comparable to that of leading GLP-1-based medicines, and we identified efficacious starting doses with placebo-like tolerability. These data position MET-233i as a potential best-in-class amylin and support a category-leading profile in combination with MET-097i.' The randomized, placebo-controlled, double-blind Phase 1 trial was designed to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous MET-233i in 80 participants with overweight or obesity without type 2 diabetes. MET-233i was evaluated at single doses from 0.15 mg to 2.4 mg, and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration. The trial population was broadly balanced in gender between MET-233i and placebo and had a mean baseline body mass index of approximately 32. Topline results from the Phase 1 trial include: Dose-linear pharmacokinetics with an observed half-life of 19 days from dose to 50% of Cmax. This represents the most durable pharmacokinetic profile of any known amylin analog and supports the potential for once-monthly dosing with simplified titration. MET-233i's exposure profile after multiple doses matched that of MET-097i, supporting combinability as a potential first-in-category once-monthly multi-NuSH combination. These data further substantiate HALO™, Metsera's proprietary, novel peptide stabilization and lipidation platform technology. Body weight loss up to 8.4%. Body weight loss was dose-dependent, ranging up to a placebo-subtracted mean of 8.4% at Day 36 after five weekly doses of 1.2 mg, with individual responses as high as 10.2%. In the single ascending dose (SAD) portion of the trial, substantial weight loss was maintained more than four weeks after dosing, supported by the ultra-long pharmacokinetics observed for MET-233i. Favorable tolerability results. Gastrointestinal adverse events in the multiple ascending dose (MAD) portion of the trial were all mild, dose-dependent, and primarily confined to the first week of dosing, implying rapid onset of tolerance despite a three-fold accumulation of exposure over five weeks. Anticipated starting doses of 0.15 mg and 0.3 mg demonstrated tolerability results comparable to placebo in both the SAD and the MAD portions of the trial. No safety signals. There were no severe or serious adverse events observed in the SAD or MAD portion of the trial to date. 'Amylin agonism has emerged as a central therapeutic mechanism for metabolic diseases, but candidates in development have been limited to weekly dosing,' said Professor Carel le Roux, Director of the Metabolic Medicine Group and Chair in Experimental Pathology at University College Dublin. 'The durability and efficacy of MET-233i in this trial, along with its combinability with Metsera's GLP-1 RA, make it the potential first monthly multi-NuSH combination candidate for patients seeking greater levels of well-tolerated weight loss with a more convenient dosing schedule.'Next StepsBased on these positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i: An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025. Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to twelve weeks, with topline data expected by year-end 2025 or early 2026. The Company also expects to report topline clinical data from its ultra-long acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025. We anticipate that MET-034i will be the third peptide engineered with Metsera's HALO™ platform to enter clinical Call and Webcast InformationMetsera will host a conference call and webcast today, June 9, 2025, at 8:00 A.M. Eastern Time to discuss the Phase 1 clinical trial of MET-233i. A live webcast of the call and a replay will be available on the Events page in the Investors & News section of the Metsera website at To access the call by phone, participants should visit this link to receive dial-in details: About MET-233i MET-233i is an ultra-long acting, subcutaneously injectable monthly amylin analog engineered for class-leading durability, potency, and combinability in solution with Metsera's fully-biased, ultra-long acting GLP-1 RA candidate MET-097i, with matched solubility parameters and observed half-lives. MET-233i is being explored in clinical studies as a monotherapy and in combination with MET-097i. Metsera is developing the combination of MET-233i and MET-097i via the FDA biologic pathway with the intent to pursue the combination's regulatory approval in the United States under a Metsera's HALO™ peptide stabilization and lipidation platformHALO™ is Metsera's novel peptide stabilization and lipidation platform technology that enables peptides to bind simultaneously to albumin and to a drug target, designed to facilitate a half-life approaching that of albumin and exceeding that of other NuSH peptides. This ultra-long half-life may enable monthly dosing, improved tolerability, and improved Metsera, is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the timelines, design and results of the Company's clinical trials and data releases; the Company's product candidate pipeline and milestone events; potential benefits of treatment with the Company's product candidates; and anticipated market opportunity and strategy. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, our limited operating history; our ability to generate revenue or become profitable; failure to obtain additional capital when needed on acceptable terms or at all; raising additional capital may cause dilution to our stockholders or require us to relinquish rights to our technologies or product candidates; our dependence on the success of our product candidates; risks associated with preclinical and clinical development; difficulties or delays in the commencement or completion, or the termination or suspension, of clinical trials; our ability to timely enroll patients in our clinical trials; if our current or future product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with the regulatory approval processes of the FDA and comparable foreign authorities; risks associated with conducting clinical trials and preclinical studies outside of the United States; our reliance on third parties to conduct clinical trials and preclinical studies; our reliance on third parties for the manufacture and shipping of our product candidates; risks associated with our license and collaboration agreements and future strategic alliances; significant competition in our industry; product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated; our success is dependent on our ability to attract and retain highly qualified management and other clinical and scientific personal; if we or our licensors are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or future product candidates or technology; risks associated with our common stock and the other important factors discussed under the caption 'Risk Factors' in its filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which are accessible on the SEC's website at and the Investors section of the Company's website at Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company's views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Contact:Jono EmmettMetseramedia@
Yahoo
23 minutes ago
- Yahoo
Amid Musk threat to decommission SpaceX Dragon, NASA reveals more Boeing Starliner delays
As the fracas between Elon Musk and President Donald Trump escalated last week to the point of Musk threatening to decommission SpaceX's Dragon spacecraft, NASA revealed even more delays to Dragon's alternative, Boeing's Starliner. 'NASA is assessing the earliest potential for a Starliner flight to the International Space Station in early 2026, pending system certification and resolution of Starliner's technical issues,' according to a statement sent to media late Friday. Though it didn't mention SpaceX specifically, the statement — coupled with Musk's threat — underscored the extraordinary degree to which NASA remains dependent on the private company for many of its key endeavors. It came after the fallout between the two powerful men sparked in part by Musk's opposition to Trump's so-call 'Big Beautiful Bill' that critics including Musk say would increase federal spending. Trump posted a threat on his Truth Social platform last week saying, 'The easiest way to save money in our Budget, Billions and Billions of Dollars, is to terminate Elon's Governmental Subsidies and Contracts. I was always surprised that Biden didn't do it!' That would include NASA's Commercial Crew Program contracts that rely on SpaceX as the lone U.S.-based option to safely fly astronauts to the International Space Station. 'In light of the President's statement about cancellation of my government contracts, @SpaceX will begin decommissioning its Dragon spacecraft immediately,' Musk posted to X in retort, although he later backed off. By now, Boeing's Starliner was supposed to have been a viable alternative sharing the taxi duties with SpaceX, but it has fallen behind Musk's company by more than five years. Last year, Starliner made its first flight with crew on board to the station, but suffered thruster issues and helium leaks on the way to docking with the station. NASA elected to send the spacecraft home without its crew, and the original plan for as short as an eight-day stay on board turned into more than nine months. While Starliner was able to make a safe landing, NASA and Boeing's path forward required not only a fix of the thruster and helium leak issues, but juggling whether or not the next flight would risk humans on board. That decision is pending, NASA said Friday. 'The agency is still evaluating whether Starliner's next flight will be in a crew or cargo configuration,' NASA stated. 'NASA astronauts are training for a Starliner post-certification mission as the agency continues to review its forward plans and execute testing campaigns targeted throughout the spring and summer.' With the continued delay, two of the crew that were looking to fly on the first operational rotational crew mission — Starliner-1 — were pulled and reassigned to the upcoming SpaceX Crew-11 mission that's targeting liftoff in late July. NASA said it has not yet determined just who will be assigned to the full Starliner-1 crew. But if the next flight is yet another uncrewed certification mission to ensure it's safe for astronauts, and that doesn't come until early 2026, then an actual operational flight would come likely no earlier than summer 2026. In the meantime, SpaceX will be relied on to continue rotational missions, although for now NASA has not announced the mission that will relieve Crew-11. If SpaceX were not a viable option, the U.S. would have to return to relying on Russia and its Soyuz spacecraft to maintain a presence on the space station. That's the situation NASA was in after the Space Shuttle Program ended in 2011. It wasn't until May 2020 when SpaceX was successful with the crewed Demo-2 mission that NASA was able to launch from the U.S. again. Since then, SpaceX has flown its fleet of four Crew Dragons 17 times carrying 64 humans to space. That includes 10 operational crew rotation missions as well as three private company visits to the space station for Axiom Space. A fifth Crew Dragon is set to launch for the first time Wednesday morning on Axiom Space's Ax-4 mission taking another four-person crew on a two-week trip to the space station. _____
